Clinical trials: copd or chronic obstructive
COPD
Bioequivalence Study of Tiotropium 18 μg Inhalation Powder, Hard Capsule With Spiriva®Handihaler® 18 μg Inhalation Powder, Hard Capsule in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Bioequivalence Study of Tiotropium Bromide Inhalation Powder 18 μg
- Trial name
- ARBORUS (NCT05986591)
- Testing
- Test Product - Tiotropium Bromide Inhalation Powder 18 mcg, Spiriva Handihaler (Tiotropium Bromide) 18 mcg
- Where
- 33 sites in United States, India
- Volunteers
- 335 people
- Sponsor
- Xiromed LLC
Chronic Obstructive Pulmonary Disease
Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD
A chronic dosing (24 weeks) study to assess the efficacy and safety GFF MDI; PT003), FF MDI; PT005, and GP MDI; PT001) in subjects with moderate to very severe COPD, compared with placebo.
- Trial name
- NCT02343458
- Testing
- GFF MDI (PT003), FF MDI (PT005), GP MDI (PT001)
- Where
- 166 sites in United States, China and 9 more
- Volunteers
- 1,756 people
- Sponsor
- Pearl Therapeutics, Inc.
Chronic Obstructive Pulmonary Disease
Characterisation of People With COPD
The investigators will describe the characteristics, prevalence, incidence, severity co-morbidity and management of patients with chronic obstructive pulmonary disease (COPD) in the UK.
- Trial name
- CoCO (NCT01263340)
- Where
- United Kingdom
- Volunteers
- 10,000 people
- Sponsor
- National Services for Health Improvement Ltd
Chronic Obstructive Pulmonary Disease (COPD)
A 42-day Parallel Group Safety Study of Revefenacin and Formoterol, Administered in Sequence and as a Combination, in Participants With COPD
The primary objective of the study was to characterize the safety and tolerability of once-daily revefenacin inhalation solution when dosed sequentially with twice-daily formoterol inhalation solution (PERFOROMIST®) compared to…
- Trial name
- NCT03573817
- Testing
- Revefenacin, Formoterol
- Where
- 12 sites in United States
- Volunteers
- 122 people
- Sponsor
- Mylan Inc.
Pulmonary Disease, Chronic Obstructive
Investigate the Impact of Early Treatment Initiation With Tiotropium in Patients Recovering From Hospitalization for an Acute COPD Exacerbation 1
A randomized, placebo-controlled, double-blind, parallel group, multi center study to assess the safety and efficacy of tiotropium bromide (18 µg) delivered via the HandiHaler® in Chronic Obstructive Pulmonary Disease (COPD)…
- Trial name
- NCT01663987
- Testing
- tiotropium bromide
- Where
- 50 sites in United States, Puerto Rico
- Volunteers
- 79 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol on Survival in Subjects With Chronic Obstructive Pulmonary Disease
The purpose of this study is to determine if fluticasone furoate/vilanterol improves survival in patients with chronic obstructive pulmonary disease with a history of or increased risk of heart disease.
- Trial name
- NCT01313676
- Testing
- fluticasone furoate/vilanterol, fluticasone furoate, vilanterol
- Where
- 1,611 sites in United States, Argentina and 42 more
- Volunteers
- 16,568 people
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease
Effect of Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Tiotropium: The HELIOS Study (BY217/M2-128)
The aim of the study is to compare the efficacy of roflumilast to placebo on pulmonary function and symptomatic parameters in patients with chronic obstructive pulmonary disease (COPD) during concomitant administration of…
- Trial name
- HELIOS (NCT00424268)
- Testing
- Roflumilast
- Where
- 103 sites in Austria, France and 5 more
- Volunteers
- 743 people
- Sponsor
- AstraZeneca
Asthma, COPD
Bioequivalence Study to Assess Systemic Exposure of FP and SAL FDC From Different DPIs
This is a crossover study to assess the systemic pharmacokinetics of fluticasone propionate (FP) and salmeterol (SAL). Study medication will be administered as fixed dose combinations (250 µg FP and 50 µg SAL) from the Advair®…
- Trial name
- NCT02215122
- Testing
- MGR001, Advair® Diskus®, Seretide™ Accuhaler™
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Mylan Pharma UK Ltd.
Chronic Obstructive Pulmonary Disease
A Scintigraphy Study of PT010 in COPD Patients
This study is a single treatment period, single dose gamma scintigraphy study investigating the deposition in the lungs of a Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (BGF-MDI).
- Trial name
- RD708/34000 (NCT03906045)
- Testing
- BGF-MDI
- Where
- 2 sites in United Kingdom
- Volunteers
- 18 people
- Sponsor
- AstraZeneca
Chronic Graft Versus Host Disease
A Study of Belumosudil in Children With Chronic Graft Versus Host Disease (schoolROCK)
This is an open-label, single group, Phase 1/2, 1-arm study for treatment of children aged 1 to <18 years with active moderate-to-severe cGVHD that is refractory to or recurred after at least 2 prior lines of systemic therapy for…
- Trial name
- schoolROCK (NCT07116031)
- Testing
- Belumosudil
- Where
- 35 sites in United States, Belgium and 11 more
- Volunteers
- 37 people
- Sponsor
- Sanofi
COPD
Study to Evaluate the Impact of the "PROactive Telecoaching Program" on Physical Activity in Patients With COPD.
This study will test two instruments to measure physical activity in COPD patients: A questionnaire and two small physical activity monitors .Patients will be randomized to either receive the telecoaching program in addition to…
- Trial name
- PROactive (NCT01992081)
- Testing
- Automated telehealth system, Usual care
- Sponsor
- Novartis Pharmaceuticals
Chronic Pain, Knee Pain Chronic
HFIT Versus TENS Study for Chronic Low Back and Knee Pain
A high-frequency impulse therapy (HFIT) device (Enso, San Francisco, CA) is a portable device for the treatment of musculoskeletal pain.
- Conditions
- Chronic Pain, Knee Pain Chronic, Back Pain, Low
- Trial name
- NCT05821530
- Testing
- HFIT, TENS, Control
- Where
- United States
- Volunteers
- 325 people
- Sponsor
- Hinge Health, Inc
Pulmonary Disease, Chronic Obstructive
A Drug Utilisation Post-authorisation Study of New Users of Aclidinium Bromide (Monotherapy or in Combination)
DUS1 and DUS2 are descriptive drug utilisation studies in new users of aclidinium bromide in Europe. The objectives of DUS1 and DUS2 are to describe the characteristics and patterns of use of new users of aclidinium bromide…
- Trial name
- DUS1/DUS2 (NCT03333018)
- Testing
- Aclidinium bromide, Aclidinium bromide/formoterol, Other COPD medication
- Where
- 3 sites in Denmark, Germany and 1 more
- Volunteers
- 22,155 people
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive
A Study To Investigate The Effect Of Inhaling A Single Dose Of GW642444M In Asthmatic Patients
This study will involve the use of a new compound, GW642444 that is being developed for the treatment of asthma and chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT00463697
- Testing
- GW642444H (100mcg), GW642444M (25, 100 & 400 mcg)
- Where
- 3 sites in United Kingdom
- Volunteers
- 20 people
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
Efficacy and Physiology of Nasal High Flow Therapy
The effects of a nasal high-flow (NHF) therapy in patients with chronic obstructive hypercapnic respiratory failure are still not sufficiently known yet.
- Trial name
- NCT02083120
- Testing
- NHF therapy, Long term Oxygen Therapy (LOT)
- Where
- Germany
- Volunteers
- 46 people
- Sponsor
- Institut für Pneumologie Hagen Ambrock eV
Pulmonary Disease, Chronic Obstructive
The Purpose of the This Study is to Evaluate the Spirometric Effect (Trough FEV1) of Umeclidinium/Vilanterol 62.5/25 mcg Once Daily Compared With Tiotropium 18mcg Once Daily Over a a 12-week Treatment Period in Subjects With COPD Who Continue to Have Symptoms on Tiotropium
The primary objective is to compare the efficacy of UMEC/VI Inhalation Powder (62.5/25 mcg) once-daily with tiotropium (18 mcg) once-daily over 12 weeks for the treatment of subjects with COPD who have received tiotropium and…
- Trial name
- NCT01899742
- Testing
- Umeclidinium/Vilanterol 62.5/25 mcg, Tiotropium 18 mcg
- Where
- 64 sites in United States, Argentina and 8 more
- Volunteers
- 497 people
- Sponsor
- GlaxoSmithKline
COPD
Tiotropium/Salmeterol/Fluticasone Fixed Dose Combination Tratment Via Discair vs Tiotropium Via Handihaler + Salmeterol/Fluticasone Via Diskus Free Combination Treatment
The overall objective is to asses the bronchodilator effect of Tiotropium/Salmeterol/Fluticasone combination delivered via Discair® twice daily as compared with original products Seretide Diskus 500 mcg Inhalation Powder twice…
- Trial name
- NCT03395002
- Testing
- Tiotropium/Salmeterol/Fluticasone 9/50/500 mcg Inhalation Powder, Tiotropium 18 mcg Inhalation Powder, Salmeterol/Fluticasone 50/500 mcg Inhalation Powder
- Where
- 2 sites in Turkey (Türkiye)
- Volunteers
- 58 people
- Sponsor
- Neutec Ar-Ge San ve Tic A.Ş
Pulmonary Disease, Chronic Obstructive
Sensor and Electronic Health Records (EHR) Integration Pilot Study
This is a pilot study that will evaluate the feasibility of collecting increasing amounts of clinical study data from subjects through sensor and web/app based methods and integrating it with data from their EHR to facilitate…
- Trial name
- NCT03357341
- Testing
- Mobile spirometer, Device sensor, Salbutamol
- Where
- United States
- Volunteers
- 194 people
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease
Clinical Efficacy and Safety Evaluation of HCP1202 in COPD Patients
A phase 3 study to evaluate efficacy and safety of HCP1202
- Trial name
- NCT02941679
- Testing
- HCP1202, HGP1011, HCP0910
- Volunteers
- 252 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Chronic Obstructive Pulmonary Disease
PT003 MDI Cardiovascular Safety Study
This study is primarily a safety study. The primary and secondary endpoints are based on 24-hour Holter monitor assessments obtained on Day 14 relative to baseline.
- Trial name
- NCT01349803
- Testing
- PT005 MDI, PT001 MDI, PT003 MDI
- Where
- 20 sites in United States, Australia and 1 more
- Volunteers
- 237 people
- Sponsor
- Pearl Therapeutics, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.